Health Trials

SNV1521 in Participants With Advanced Solid Tumors

ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorSynnovation Therapeutics, Inc.

About this trial

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the most effective and safe one. They are also investigating whether it can be combined with other cancer therapies.

Eligibility criteria

Qualifiers

Advanced or metastatic solid tumor malignancy

Evaluable or Measurable disease (RECIST 1.1 Criteria).

ECOG Performance Status 0 or 1.

Life expectancy > 3 months

Disqualifiers

History of other malignancy within the past 2 years

Prior diagnosis of Myelodysplastic syndrome or Acute Myeloid Leukemia

Significant cardiovascular disease within 6 months

Significant gastrointestinal disease

Trial design

Treatments tested in this trial

  • SNV1521
  • DB-1310
  • Abiraterone
  • Darolutamide

Treatment groups

400 Participants
are divided into 10 treatment groups

10

Treatment groups

See each treatment group below.

Locations

25
Australia
Scientia Clinical Research2031, RandwickNew South Wales, Australia
Princess Alexandra Hospital4102, WoolloongabbaQueensland, Australia
Monash Health3168, ClaytonVictoria, Australia
The Alfred Hospital3004, MelbourneVictoria, Australia

Sponsors and collaborators

Synnovation Therapeutics, Inc.

Lead sponsor

Source ClinicalTrials.gov